Current Science

Open Access Open Access  Restricted Access Subscription Access

Potent Antitumour Activity of (-)Epigallocatechin Gallate: Indications from In Vitro, In Vivo and in Silico Studies


Affiliations
1 Department of Biotechnology, Center for Post-Graduate Studies, Jain University, Bengaluru 560 011, India
2 Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
3 Institute of Molecular and Cell Biology, Biopolis, Singapore
 

Antitumour efficacy of (-)epigallocatechin-3-gallate (EGCG) was evaluated in vitro against the cancer cell lines BxPC-3 (pancreatic cancer), A549 (lung cancer), SH-SY5Y (neuroblastoma), MDA-MB-231 and MCF-7 (breast cancer); in vivo in nude mice by tumour growth inhibition of pancreatic cancers (BxPC-3, MIAPaCa-2), breast cancer (MDA-MB-231), and in silico by docking studies. EGCG significantly inhibited these cancer cell lines in vitro and showed significant tumour reduction in vivo. EGCG docked on to the Her-2 receptor (1N8Y) and the tubulin dimer receptor at a site other than the existing docetaxel ligand. Overall our results suggest that EGCG has potent antineoplastic activity.

Keywords

Antitumour Efficacy, Breast Cancer, Docking, Epigallocatechin Gallate, Lung Cancer.
User
Notifications
Font Size

  • Fact sheets by cancer, International Agency for Research on Cancer, France; http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; (updated January 2015; cited 14 February 2015).

  • Vu, H. A. et al., Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. J. Biomed. Biotechnol., 2010, 290516.

  • Tang, S. N., Fu, J., Shankar, S. and Srivastava, R. K., EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS ONE, 2012, 7, 31067.

  • Asano, Y., Okamura, S., Ogo, T., Eto, T., Otsuka, T. and Niho, Y., Effect of (-)-epigallocatechin gallate on leukemic blast cells from patients with acute myeloblastic leukemia. Life Sci., 1997, 60, 135-142.

  • Hibasami, H. et al., Induction of apoptosis in human stomach cancer cells by green tea catechins. Oncol. Rep., 1998, 5, 527-529.

  • Paschka, A. G., Butler, R. and Young, C. Y., Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)epigallocatechin-3-gallate. Cancer Lett., 1998, 130, 1-7.

  • Hyams, J. S. and Stebbings, H., The mechanism of microtubule associated cytoplasmic transport. Isolation and preliminary characterisation of a microtubule transport system. Cell Tissue Res., 1979, 196, 103-116.

  • Valiron, O., Caudron, N. and Job, D., Microtubule dynamics. Cell Mol. Life Sci., 2001, 58, 2069-2084.

  • Sengupta, S. and Thomas, S. A., Drug target interaction of tubulinbinding drugs in cancer therapy. Expert Rev. Anticancer, 2006, 6, 1433-1447.

  • Lee, S. C. et al., Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgenindependent prostate cancer in vivo. Nutr. Cancer, 2008, 60, 483- 491.

  • Teicher, B. A. (ed.), Tumor Models in Cancer Research, Humana Press, Totowa, NJ, 2011; http://link.springer.com/10.1007/978-160761-968-0 (cited 14 February 2015).

  • Pople, J. A., Head‐Gordon, M., Fox, D. J., Raghavachari, K., Curtiss, L. A., Gaussian‐1 theory: a general procedure for prediction of molecular energies. J. Chem. Phys., 1989, 90, 5622-5629.

  • Arguslab; http://www.arguslab.com/arguslab.com/ArgusLab.html (cited 14 February 2014).

  • Ritchie, D. W. and Venkatraman, V., Ultra-fast FFT protein docking on graphics processors. Bioinformatics, 2010, 26, 2398-2405.

  • Cho, H. S. et al., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 2003, 421, 756-760.

  • Nogales, E., Wolf, S. G. and Downing, K. H., Structure of the alpha beta tubulin dimer by electron crystallography. Nature, 1998, 391, 199-203.

  • Chan, M. M., Soprano, K. J., Weinstein, K. and Fong, D., Epigallocatechin3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J. Cell. Physiol., 2006, 207, 389-396.

  • Li, G. X. et al., Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis, 2010, 31, 902-910.

  • Baliga, M. S., Meleth, S. and Katiyar, S. K., Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasisspecific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin. Cancer Res., 2005, 11, 1918-1927.

  • Canete, A. et al., Poor survival for infants with MYCN amplified metastatic neuroblastoma despite intensified treatment: The International Society of Pediatric Oncology European Neuroblastoma Experience. J. Clin. Oncol., 2009, 27, 1014-1019.


Abstract Views: 331

PDF Views: 97




  • Potent Antitumour Activity of (-)Epigallocatechin Gallate: Indications from In Vitro, In Vivo and in Silico Studies

Abstract Views: 331  |  PDF Views: 97

Authors

Samarendra Narayanan
Department of Biotechnology, Center for Post-Graduate Studies, Jain University, Bengaluru 560 011, India
Balaji Ramchandran
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Satheesh Rajendiran
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Sarbani Chandra
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Atul Tiwari
Department of Biology, Syngene International Limited, Jigani Link Road, Bengaluru 560 011, India
Ravisankar Rajarethinam
Institute of Molecular and Cell Biology, Biopolis, Singapore
Ramesh Kureeckal Vasudev
Department of Biotechnology, Center for Post-Graduate Studies, Jain University, Bengaluru 560 011, India

Abstract


Antitumour efficacy of (-)epigallocatechin-3-gallate (EGCG) was evaluated in vitro against the cancer cell lines BxPC-3 (pancreatic cancer), A549 (lung cancer), SH-SY5Y (neuroblastoma), MDA-MB-231 and MCF-7 (breast cancer); in vivo in nude mice by tumour growth inhibition of pancreatic cancers (BxPC-3, MIAPaCa-2), breast cancer (MDA-MB-231), and in silico by docking studies. EGCG significantly inhibited these cancer cell lines in vitro and showed significant tumour reduction in vivo. EGCG docked on to the Her-2 receptor (1N8Y) and the tubulin dimer receptor at a site other than the existing docetaxel ligand. Overall our results suggest that EGCG has potent antineoplastic activity.

Keywords


Antitumour Efficacy, Breast Cancer, Docking, Epigallocatechin Gallate, Lung Cancer.

References





DOI: https://doi.org/10.18520/cs%2Fv110%2Fi2%2F187-195